Search Results
Oct 17, 2025, 09:00 ET ororo Expands Workwear Collection with Three New Durable and Comfortable Styles for Everyday Wear
heating, and the Dual-Control capabilities allow customers to choose which heating zones they would like to activate. Powered by ororo's UL-Certified PD 5K rechargeable battery, the Wayne Full-Zip Hoodie is available in sizes Small through 5XL. The
More news about: ORORO Heated Apparel
Oct 17, 2025, 08:00 ET Marengo Presents Initial Phase 2 Results Demonstrating Broad Single-Agent Activity of Invikafusp Alfa Across Multiple PD-1-Refractory or -Resistant Solid Tumors as a Late-Breaking Oral Presentation at ESMO 2025
ORR (3/10) and 70% DCR (7/10). Clinical efficacy was observed in PD-1-resistant/refractory tumors and PD-1 naive tumors where PD-1 was not approved as standard of care, confirming PD-1-independent activity. The safety profile was consistent with selective
More news about: Marengo Therapeutics
Oct 16, 2025, 23:13 ET Wang Qunbin: Innovation-Driven, Fosun's Path to Globalization
field of innovative drugs. HLX43, a PD-L1-targeting antibody-drug conjugate (ADC) is undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma in countries including China, the United States, Japan, and Australia. Currently, no PD-L1 ADC has been approved globally,
More news about: Fosun
Oct 16, 2025, 10:30 ET Anvisa aprova nova indicação para durvalumabe da AstraZeneca que reduz em 32% o risco de recidiva no câncer de pulmão operável[1]
de fase 3 que avaliou o uso de durvalumabe antes e depois da cirurgia em pacientes com câncer de pulmão operável, independentemente da expressão de PD-L1. Os participantes foram tratados com quatro ciclos de durvalumabe + quimioterapia antes da cirurgia e, após o procedimento, com durvalumabe isoladamente
More news about: AstraZeneca
Oct 16, 2025, 09:46 ET First Responders Children's Foundation Announces Jon Stewart as Host and Master of Ceremonies for National First Responders Day
was shot in the leg. Returning fire, Officer Wong neutralized the suspect. MTA PD: Officers Scott Gulick & Christopher CapozzoliMetropolitan Transportation Authority Police Dept., New York, NY
More news about: First Responders Children's Foundation
Oct 16, 2025, 08:35 ET Unixell Biotech reported a case study of UX-DA001, an iPSC-derived autologous cell therapy for Parkinson Diseases at MDS Congress 2025
Parkinson's disease (PD) and other neurological disorders, announced positive 6-month follow-up data from the first patient in its phase 1 clinical trial for UX-DA001, an iPSC-derived autologous cell therapy for PD. These data were presented on October 8th at the International
More news about: UniXell Biotechnology
Oct 16, 2025, 03:00 ET Power Metallic Initiates Metallurgical Testing of Lion Deposit Phase 1 Metallurgy Recovery Contracted to SGS Canada Inc., Quebec City, QC and Lakefield, ON
the three composites will go through complete metallurgical testing for determining any variability for recovery of the six (6) principal metals (Cu, Pd, Pt, Au, Ag, Ni) for each zone and for the Blended composite. Additional testing may be done for rare earth minerals associated with this polymetallic
More news about: Power Metallic Mines Inc.
Oct 16, 2025, 00:15 ET HARMONi-6 Phase III Study of Ivonescimab Accepted by The Lancet and Selected for ESMO 2025 LBA Presentation
success in the head-to-head study against pembrolizumab as first-line treatment for PD-L1-positive NSCLC. This Phase III study has now demonstrated positive outcomes in a comparison of ivonescimab plus chemotherapy versus PD-1 inhibitor plus chemotherapy for the first-line treatment of squamous NSCLC, addressing
More news about: Akeso, Inc.
Oct 15, 2025, 12:44 ET Florida Cancer Specialists & Research Institute Champions the Impact of Integrated Oncology At NCODA International Summit
"Redefining the Treatment of Squamous Cell Carcinoma of the Anal Canal (SCAC) ZYNYZ® (retifanlimab-dlwr): The First and Only FDA-Approved PD-1 Inhibitor for Adults with Inoperable Locally Recurrent or Metastatic SCAC."
More news about: Florida Cancer Specialists & Research Institute
Oct 15, 2025, 12:00 ET GIGABYTE Announces Availability of GAMING A16 PRO and GAMING A18 Laptops
immersive experience, making it ideal for both gaming and productivity-focused users who prioritize screen real estate. With Type-C PD 3.0 fast charging support and all-day battery performance, the GAMING A16 PRO and GAMING A18 are designed to balance performance, endurance, and mobility.
More news about: GIGABYTE
Oct 15, 2025, 12:00 ET GIGABYTE Announces Availability of GAMING A16 PRO and GAMING A18 Laptops
immersive experience, making it ideal for both gaming and productivity-focused users who prioritize screen real estate. With Type-C PD 3.0 fast charging support and all-day battery performance, the GAMING A16 PRO and GAMING A18 are designed to balance performance, endurance, and mobility.
More news about: GIGABYTE
Oct 15, 2025, 10:40 ET Commercial Distributed Energy Generation Market Size Worth USD 367.8 Billion by 2033, Growing at 11.0% CAGR from 2026-2033 : - Market Research Intellect
Market Size By Application (Lung Cancer, Melanoma, Bladder Cancer, Hodgkin Lymphoma, Head and Neck Cancers), By Product (PD-1 Inhibitors (Programmed Cell Death Protein 1), PD-L1 Inhibitors (Programmed Death-Ligand 1), CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein 4), Combination Therapies,
More news about: Market Research Intellect
Oct 15, 2025, 09:11 ET Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
President and Chief Scientific Officer of Regeneron. "Now with five FDA-approved indications, Libtayo is firmly established as a strong and versatile PD-1 inhibitor option for patients with a variety of cancers." An additional regulatory application is under review in the European
More news about: USA News Group
Oct 15, 2025, 08:00 ET OncoHost to Present New Research on Plasma Proteomics-Based Treatment Selection in Melanoma at ESMO 2025
observational study, pre-treatment plasma samples were collected from 248 patients with metastatic melanoma treated with anti-PD1 monotherapy (pembrolizumab or nivolumab) or anti-PD1 + anti-CTLA4 combination (ipilimumab + nivolumab) were analyzed. Key findings
More news about: OncoHost
Oct 15, 2025, 07:30 ET Endo Announces Peyronie's Disease Presentation at the North Central Section of the American Urological Association
effective and well tolerated in men with PD and VC, supporting its continued use as a nonsurgical treatment option for this population. About Peyronie's Disease Peyronie's disease (PD) is a condition in which a buildup of fibrous
More news about: Endo USA, Inc.
Oct 15, 2025, 07:00 ET Marengo Therapeutics to Present Key Pipeline Updates at 2025 SITC Annual Meeting and Reveal First Asset from TriSTAR™ Platform Targeting Nectin-4
Title: Triple combination therapy with a TCR Vb-directed bifunctional molecule, cisplatin and anti-PD-1 in immune checkpoint blockade-refractory head and neck murine tumor models Abstract Number: 629
More news about: Marengo Therapeutics
Oct 15, 2025, 04:00 ET Gravity Launches Strategic Card Battle Game "Chess Rumble" Worldwide
top 30 players. Users can also take part in the large-scale weekly "Gold Rush" event for even more competitive fun. Jinung Ju, PD of Chess Rumble at Gravity, said, "As a card battle game, Chess Rumble is easy and enjoyable for anyone who enjoys strategy and card gameplay. In particular,
More news about: Gravity
Oct 15, 2025, 04:00 ET Gravity veröffentlicht das strategische Kartenspiel „Chess Rumble" weltweit
angelegten wöchentlichen „Gold Rush"-Event teilnehmen, um noch mehr kompetitiven Spaß zu erleben. Jinung Ju, PD von Chess Rumble bei Gravity, erklärte: „Chess Rumble ist ein Kartenspiel, das für alle, die Strategie- und Kartenspiele mögen, leicht zu erlernen und
More news about: Gravity
Oct 15, 2025, 04:00 ET Gravity Launches Strategic Card Battle Game "Chess Rumble" Worldwide
top 30 players. Users can also take part in the large-scale weekly "Gold Rush" event for even more competitive fun. Jinung Ju, PD of Chess Rumble at Gravity, said, "As a card battle game, Chess Rumble is easy and enjoyable for anyone who enjoys strategy and card gameplay. In particular,
More news about: Gravity
Oct 15, 2025, 04:00 ET Gravity lanza a nivel mundial el juego de batallas de cartas estratégico "Chess Rumble"
semanal a gran escala "Fiebre del Oro" para disfrutar de una diversión aún más competitiva. Jinung Ju, PD de Chess Rumble en Gravity, comentó, "Como juego de batallas de cartas, Chess Rumble es fácil y divertido para quienes disfrutan de la estrategia y el
More news about: Gravity
Oct 15, 2025, 04:00 ET Gravity lança mundialmente o jogo estratégico de batalha com cartas "Chess Rumble"
em grande escala "Gold Rush" para ainda mais diversão competitiva. Jinung Ju, PD de Chess Rumble na Gravity, disse: "Como um jogo de batalha de cartas, Chess Rumble é fácil e agradável para qualquer pessoa que goste de estratégia
More news about: Gravity
Oct 15, 2025, 03:30 ET Mission Therapeutics raises $13.3 million to progress first-in-class Parkinson's disease candidate MTX325 through clinical trials
MTX325 in patients with Parkinson's disease (PD) Comes after successful completion of Phase 1a studies of MTX325, a first-in-class and potentially disease-modifying treatment for PD, in healthy volunteers
More news about: Mission Therapeutics
Oct 14, 2025, 09:05 ET Freespira Introduces the Zero Risk Program for Health Plans, a First for Mental Health Devices
14, 2025 /PRNewswire/ -- Freespira, Inc., developer of the first FDA-cleared at-home treatment for anxiety disorders including panic disorder (PD), and post-traumatic stress disorder (PTSD), today announced the launch of the Freespira Zero Risk program for health plans. Following the consistently
More news about: Freespira, Inc.
Oct 14, 2025, 08:10 ET Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer
(valacyclovir) has been granted Fast Track Designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy and localized primary
More news about: Trinity Capital Inc.
Oct 14, 2025, 02:20 ET 華上生醫抗癌新藥GNTbm-TKI將在ESMO發表
細胞的生成，以及強力抑制免疫抑制型細胞被腫瘤吸引至腫瘤微環境中。另一方面，研究也顯示GNTbm-TKI + GNTbm-38 聯合抗 PD-1/VEGF 雙特異性抗體，在人源化 B-PD-1/PD-L1/VEGFA 小鼠模型中，也極大地改善了抗癌效果，表現出強烈的協同增效作用。 GNTbm-TKI 是一種強效的免疫活化多激酶抑制劑，且發現其在與 GNTbm-38 聯合使用時能顯著重塑腫瘤微環境。當進一步與 ICI 或抗 PD-1/VEGF 雙特異性抗體聯合時，能大幅提升抗癌療效，為未來臨床試驗提供科學依據。
More news about: 華上生醫